Drug Trial Radar · NCT06888921
A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer
Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Jul 21, 2025
Primary completion
Mar 2027
Study completion Mar 2027
Sponsor
- Lead sponsor
- Compugen LtdIndustry
- Sponsor type
- Industry
- First posted
- Mar 21, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if the experimental antibody COM701 delays the progression of ovarian cancer in participants with Relapsed Platinum Sensitive Ovarian Cancer. It will also learn about the safety of COM701. The main questions the trial aims to answer are: * Does COM701, when used as a maintenance treatment, stop or slow the progression of ovarian cancer? * Does COM701 delay the time to needing a new anti-cancer treatment? * What side effects do participants have when taking COM701? Participants will: * Visit the clinic once every 3 weeks during which the study treatment will be administered intravenously * Undergo various tests and procedures to monitor general health throughout the trial including physical examinations, vital sign measurements (heart rate, blood pressure, breathing, and body temperature), weight measurements, electrocardiography (ECG), blood and urine tests and pregnancy tests if relevant. * Undergo various tests and procedures to assess disease response throughout the trial including tumor imaging by CT scans or MRI to assess the tumor, its location, and size, and the testing of a sample of tumor tissue (from a prior biopsy or a fresh biopsy if feasible, to evaluate tumor response to treatment and to measure levels of tumor markers,
Conditions
- Ovarian Cancer
- Ovarian Cancer Recurrent
Interventions
COM701Drug
COM701 will be administered via intravenous (IV) infusion once every 3 weeks.
Normal SalineDrug
Saline will be administered via intravenous (IV) infusion once every 3 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the effect of COM701 as a single agent on progression free survival when administered as a maintenance regimen in participants with relapsed PSOCTime frame: From the date of randomization until the date of disease progression, or date of death from any cause whichever occurs first, assessed up to 2 years
Locations
27 sites in 3 countries. Site status is shown where the registry gives one.
Georgia Cancer Center at Augusta University
Augusta, Georgia
The University of Chicago Medical Center
Chicago, Illinois
Northwestern Memorial Hospital
Warrenville, Illinois
Massachusetts General Hospital
Boston, Massachusetts
Corewell Health
Grand Rapids, Michigan
Memorial Sloan Kettering Cancer Center- Main Campus
New York, New York
University of Rochester Medical Center
Rochester, New York
Levine Cancer Institute
Charlotte, North Carolina
Ohio State University Wexner Medical Center Gynecologic Oncology at Mill Run
Hilliard, Ohio
OU Health Stephenson Cancer Center
Oklahoma City, Oklahoma
UPMC Magee- Womens Hospital
Pittsburgh, Pennsylvania
Avera Cancer Institute
Sioux Falls, South Dakota
UVA Comprehensive Cancer Center
Charlottesville, Virginia
Centre Oscar Lambret
Lille, France
Institut Paoli-Calmettes
Marseille, France
Hospices Civils de Lyon- Centre Hospitalier Lyon Sud
Pierre-Bénite, France
Centre Eugene Marquis
Rennes, France
Institut de Cancerologie de l'Ouest- Site Rene Gauducheau
Saint-Herblain, France
Gustave Roussy
Villejuif, France
Centre Hospitalier Regional et Universitaire de Besancon - Hopital Jean-Minjoz
Besançon, France, France
Oncopole Claudius Regaud
Toulouse, France, France
Assuta Medical Center
Ashdod, Israel
Rambam Health Care Campus
Haifa, Israel
The Edith Wolfson Medical Center
Holon, Israel
Shaare Zedek Medical Center
Jerusalem, Israel
Hadassah, University Hospital Ein Kerem
Jerusalem, Israel
The Chaim Sheba Medical Center
Ramat Gan, Israel
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.